{"id":"W4381548535","doi":"10.1136/jitc-2022-006589","title":"G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Astellas Pharma; Daiichi-Sankyo; Genentech; Coherus Biosciences; Servier; Moderna; Revolution Medicines; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Mallinckrodt Pharmaceuticals; Boston Scientific Corporation; Pharmavite; Ludwig Center at Harvard; GlaxoSmithKline; Pfizer; Break Through Cancer; National Institute of Allergy and Infectious Diseases; Celgene","keywords":"FOLFIRINOX; Pegfilgrastim; Medicine; Filgrastim; Gemcitabine; Immunology; Pancreatic cancer; Neutropenia; Granulocyte colony-stimulating factor; Chemotherapy; Cancer research; Internal medicine; Cancer; Irinotecan","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008269027,0.0002277298,0.0007087917,0.0004645432,0.0001627649,0.00001804317,0.0004611068,0.0002509388,0.0002205109],"category_scores_gemma":[0.00004695031,0.0001965096,0.0001934727,0.0003655441,0.0001206127,0.0001498939,0.00008807012,0.0004173378,0.00001644284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000153081,"about_ca_system_score_gemma":0.0001727759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004973367,"about_ca_topic_score_gemma":0.0001176756,"domain_scores_codex":[0.9980528,0.0001521746,0.000989099,0.0002537236,0.00009093594,0.0004612134],"domain_scores_gemma":[0.9987966,0.0001936862,0.0004325898,0.0003167496,0.0002363964,0.00002391841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00236962,0.00004925371,0.00202795,0.0001510538,0.0002173388,0.000002180197,0.001895665,0.0002137824,0.9767694,0.0000469691,0.002100433,0.01415634],"study_design_scores_gemma":[0.0055673,0.0006504686,0.03037407,0.001177989,0.00003900418,0.00005472982,0.0004426881,0.000005570568,0.9459298,0.00009550207,0.01542725,0.0002355919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9548092,0.04088762,0.00003172879,0.0004429528,0.003078923,0.0006163662,0.00004109335,0.00002134314,0.00007080327],"genre_scores_gemma":[0.9899384,0.00686651,0.00007365008,0.00009842075,0.00006225151,0.000102322,0.000009048398,0.00005663144,0.002792731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03512927,"threshold_uncertainty_score":0.8013429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02184843116684437,"score_gpt":0.323270584917015,"score_spread":0.3014221537501707,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}